Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials

We assessed dysglycemia and a T1D Diagnostic Index60 (Index60) ≥1.00 (on the basis of fasting C-peptide, 60-min glucose, and 60-min C-peptide levels) as prediagnostic end points for type 1 diabetes among Type 1 Diabetes TrialNet Pathway to Prevention Study participants. Two cohorts were analyzed: )...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes care 2017-11, Vol.40 (11), p.1494-1499
Hauptverfasser: Nathan, Brandon M, Boulware, David, Geyer, Susan, Atkinson, Mark A, Colman, Peter, Goland, Robin, Russell, William, Wentworth, John M, Wilson, Darrell M, Evans-Molina, Carmella, Wherrett, Diane, Skyler, Jay S, Moran, Antoinette, Sosenko, Jay M
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Blood Glucose - metabolism
C-Peptide - blood
Child
Child, Preschool
Cohort Studies
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 1 - blood
Diabetes Mellitus, Type 1 - diagnosis
Diagnostic systems
Disease control
Endpoint Determination
Epidemiology/Health Services Research
Follow-Up Studies
Glucose
Glucose tolerance
Glucose Tolerance Test
Health risks
Humans
Incidence
Infant
Middle Aged
Peptides
Prevention
Research design
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We assessed dysglycemia and a T1D Diagnostic Index60 (Index60) ≥1.00 (on the basis of fasting C-peptide, 60-min glucose, and 60-min C-peptide levels) as prediagnostic end points for type 1 diabetes among Type 1 Diabetes TrialNet Pathway to Prevention Study participants. Two cohorts were analyzed: ) baseline normoglycemic oral glucose tolerance tests (OGTTs) with an incident dysglycemic OGTT and ) baseline Index60
ISSN:0149-5992
1935-5548
DOI:10.2337/dc17-0916